Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach

References

• Ebrahimi M, Moazzen F, Marmari V, et al. In silico analysis, cloning and expression of recombinant CD166 in E. coli BL21 (DE3) as a marker for detection and treatment of colorectal cancer. J Med Microbiol Diagnosis. 2017;06(01):1–6. doi:10.4172/2161-0703.1000249
   Google Scholar
• Vries RGJ, Huch M, Clevers H. Stem cells and cancer of the stomach and intestine. Mol Oncol. 2010;4(5):373–384. doi:10.1016/j.molonc.2010.05.00120598659
   PubMedGoogle Scholar
• Dana H. An overview of cancer stem cell. J Stem Cell Res Ther. 2017;1(4):169–174. doi:10.15406/jsrt.2016.01.00029
   Google Scholar
• Zhang X, Li X, You Q, Zhang X. Prodrug strategy for cancer cell-specific targeting: a recent overview. Eur J Med Chem. 2017;139:542–563. doi:10.1016/j.ejmech.2017.08.01028837920
   PubMed Web of Science ®Google Scholar
• Hassanpour SH, Dehghani M. Review of cancer from perspective of molecular. J Cancer Res Pract. 2017;4(4):127–129. doi:10.1016/j.jcrpr.2017.07.001
   Google Scholar
• Saraswathy M, Gong S. Recent developments in the co-delivery of siRNA and small molecule anticancer drugs for cancer treatment. Mater Today. 2014;17(6):298–306. doi:10.1016/j.mattod.2014.05.002
   Web of Science ®Google Scholar
• Endoh T, Ohtsuki T. Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv Drug Deliv Rev. 2009;61(9):704–709. doi:10.1016/j.addr.2009.04.00519383521
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi:10.3322/caac.2120824399786
   PubMed Web of Science ®Google Scholar
• Spano J-P, Azria D, Gonçalves A. Patients’ satisfaction in early breast cancer treatment: change in treatment over time and impact of HER2-targeted therapy. Crit Rev Oncol Hematol. 2015;94(3):270–278. doi:10.1016/j.critrevonc.2015.01.00725682223
   PubMedGoogle Scholar
• Wee Gan C, Chien S, Feng -S-S. Nanomedicine: enhancement of chemotherapeutical efficacy of docetaxel by using a biodegradable nanoparticle formulation. Curr Pharm Des. 2010;16(21):2308–2320. doi:10.2174/13816121079192048720618152
   PubMedGoogle Scholar
• Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. MAbs. 2013;6(1):34–45. doi:10.4161/mabs.27022
   Web of Science ®Google Scholar
• Leal M, Sapra P, Hurvitz SA, et al. Antibody–drug conjugates: an emerging modality for the treatment of cancer. Ann N Y Acad Sci. 2014;1321(1):41–54. doi:10.1111/nyas.1249925123209
   PubMedGoogle Scholar
• Jain S, Pathak K, Vaidya A. Molecular therapy using siRNA: recent trends and advances of multi target inhibition of cancer growth. Int J Biol Macromol. 2018;116:880–892. doi:10.1016/j.ijbiomac.2018.05.07729782974
   PubMed Web of Science ®Google Scholar
• Mahmoodzad H, Ardaneh M, Zeinalinia E, et al. Microrna a new gate in cancer and human disease: a review. J Biol Sci. 2017;17(6):247–254. doi:10.3923/jbs.2017.247.254
   Google Scholar
• Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806. doi:10.1038/358889486653
   PubMed Web of Science ®Google Scholar
• Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci. 2001;98(17):9742–9747. doi:10.1073/pnas.17125179811481446
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411(6836):494–498. doi:10.1038/3507810711373684
   PubMed Web of Science ®Google Scholar
• Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet. 2007;8(3):173–184. doi:10.1038/nrg200617304245
   PubMed Web of Science ®Google Scholar
• Dana H, Chalbatani GM, Mahmoodzadeh H, et al. Molecular mechanisms and biological functions of siRNA. Int J Biomed Sci. 2017;13(2):48–57.28824341
   PubMedGoogle Scholar
• Yang J. Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis. Expert Rev Clin Pharmacol. 2019;12(2):95–99. doi:10.1080/17512433.2019.156732630644768
   PubMed Web of Science ®Google Scholar
• Lorenzer C, Dirin M, Winkler AM, Baumann V, Winkler J. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics. J Control Release. 2015;203:1–15. doi:10.1016/j.jconrel.2015.02.00325660205
   PubMed Web of Science ®Google Scholar
• Hong CA, Nam YS. Functional nanostructures for effective delivery of small interfering RNA therapeutics. Theranostics. 2014;4(12):1211–1232. doi:10.7150/thno.849125285170
   PubMedGoogle Scholar
• Lee S-Y, Lee SJ, Oh Y-K, et al. Stability and cellular uptake of polymerized siRNA (poly-siRNA)/polyethylenimine (PEI) complexes for efficient gene silencing. J Control Release. 2009;141(3):339–346. doi:10.1016/j.jconrel.2009.10.00719836427
   PubMedGoogle Scholar
• Sjouke B, Balak DMW, Beuers U, Ratziu V, Stroes ESG. Is mipomersen ready for clinical implementation? A transatlantic dilemma. Curr Opin Lipidol. 2013;24:4. doi:10.1097/MOL.0b013e328362dfd923298958
   PubMedGoogle Scholar
• Burnett J, Rossi J. RNA-based therapeutics: current progress and future prospects. Chem Biol. 2012;19(1):60–71. doi:10.1016/j.chembiol.2011.12.00822284355
   PubMed Web of Science ®Google Scholar
• Biswas S, Deshpande PP, Navarro G, Dodwadkar NS, Torchilin VP. Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery. Biomaterials. 2013;34(4):1289–1301. doi:10.1016/j.biomaterials.2012.10.02423137395
   PubMed Web of Science ®Google Scholar
• Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2):129–138. doi:10.1038/nrd274219180106
   PubMed Web of Science ®Google Scholar
• Rettig GR, Behlke MA. Progress toward in vivo use of siRNAs-II. Mol Ther. 2012;20(3):483–512. doi:10.1038/mt.2011.26322186795
   PubMed Web of Science ®Google Scholar
• Tsunoda S, Mazda O, Oda Y, et al. Sonoporation using microbubble BR14 promotes pDNA/siRNA transduction to murine heart. Biochem Biophys Res Commun. 2005;336(1):118–127. doi:10.1016/j.bbrc.2005.08.05216125678
   PubMed Web of Science ®Google Scholar
• Kishida T, Asada H, Gojo S, et al. Sequence-specific gene silencing in murine muscle induced by electroporation-mediated transfer of short interfering RNA. J Gene Med. 2004;6(1):105–110. doi:10.1002/jgm.45614716682
   PubMedGoogle Scholar
• Morrissey DV, Blanchard K, Shaw L, et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology. 2005;41(6):1349–1356. doi:10.1002/hep.2070215880588
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhao B, Jiang H, Wang B, Ma B. Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Release. 2007;123(1):1–10. doi:10.1016/j.jconrel.2007.07.01617716771
   PubMed Web of Science ®Google Scholar
• Kim WJ, Kim SW. Efficient siRNA delivery with non-viral polymeric vehicles. Pharm Res. 2009;26(3):657–666. doi:10.1007/s11095-008-9774-119015957
   PubMed Web of Science ®Google Scholar
• Gary DJ, Puri N, Won YY. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control Release. 2007;121(1–2):64–73. doi:10.1016/j.jconrel.2007.05.02117588702
   PubMed Web of Science ®Google Scholar
• Tseng YC, Mozumdar S, Huang L. Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev. 2009;61(9):721–731. doi:10.1016/j.addr.2009.03.00319328215
   PubMed Web of Science ®Google Scholar
• Hassani Z, Lemkine GF, Erbacher P, et al. Lipid-mediated siRNA delivery down-regulates exogenous gene expression in the mouse brain at picomolar levels. J Gene Med. 2005;7(2):198–207. doi:10.1002/jgm.65915515135
   PubMed Web of Science ®Google Scholar
• Simeoni F, Morris MC, Heitz F, Divita G. Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res. 2003;31(11):2717–2724. doi:10.1093/nar/gkg38512771197
   PubMed Web of Science ®Google Scholar
• Simeoni F, Morris MC, Heitz F, Divita G. Peptide-based strategy for siRNA delivery into mammalian cells BT - RNA silencing: methods and protocols In: Carmichael GG, Totowa NJ, editors. Vol. 309. Humana Press; 2005:251–260. doi:10.1385/1-59259-935-4:251.
   Google Scholar
• Farrow B, Evers BM, Iwamura T, Murillo C, O’Connor KL, Rychahou P. Inhibition of pancreatic cancer cell growth and induction of apoptosis with novel therapies directed against protein kinase A. Surgery. 2003;134(2):197–205. doi:10.1067/msy.2003.22012947318
   PubMed Web of Science ®Google Scholar
• Schwarz DS, Hutvágner G, Haley B, Zamore PD. Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Mol Cell. 2002;10(3):537–548. doi:10.1016/S1097-2765(02)00651-212408822
   PubMed Web of Science ®Google Scholar
• Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides. 2008;18(4):305–320. doi:10.1089/oli.2008.016419025401
   PubMed Web of Science ®Google Scholar
• Chiu Y, Rana TM. siRNA function in RNAi: a chemical modification analysis. Rna. 2003;9:1034–1048. doi:10.1261/rna.5103703.200012923253
   PubMed Web of Science ®Google Scholar
• Hall AHS, Wan J, Shaughnessy EE, Shaw BR, Alexander KA. RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res. 2004;32(20):5991–6000. doi:10.1093/nar/gkh93615545637
   PubMed Web of Science ®Google Scholar
• Dowler T, Bergeron D, Tedeschi AL, Paquet L, Ferrari N, Damha MJ. Improvements in siRNA properties mediated by 2′-deoxy-2′-fluoro-β-D-arabinonucleic acid (FANA). Nucleic Acids Res. 2006;34(6):1669–1675. doi:10.1093/nar/gkl03316554553
   PubMed Web of Science ®Google Scholar
• Watts JK, Deleavey GF, Damha MJ. Chemically modified siRNA: tools and applications. Drug Discov Today. 2008;13(19–20):842–855. doi:10.1016/j.drudis.2008.05.00718614389
   PubMed Web of Science ®Google Scholar
• Xu C, Wang J. Delivery systems for siRNA drug development in cancer therapy. Asian J Pharm Sci. 2015;10(1):1–12. doi:10.1016/j.ajps.2014.08.011
   Web of Science ®Google Scholar
• Ghafouri-Fard S, Ghafouri-Fard S. siRNA and cancer immunotherapy. Immunotherapy. 2012;4(9):907–917. doi:10.2217/imt.12.8723046235
   PubMedGoogle Scholar
• Klippstein R, Pozo D. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine Nanotechnology Biol Med. 2010;6(4):523–529. doi:10.1016/j.nano.2010.01.001
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunology. Nature. 1998;392:245–252. doi:10.1038/325889521319
   PubMed Web of Science ®Google Scholar
• Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Pathology. 2000;245–273. doi:10.1146/annurev.immunol.21.120601.14104011186419
   PubMedGoogle Scholar
• Constantino J, Gomes C, Falcão A, Neves BM, Cruz MT. Dendritic cell-based immunotherapy: a basic review and recent advances. Immunol Res. 2017;65(4):798–810. doi:10.1007/s12026-017-8931-128660480
   PubMed Web of Science ®Google Scholar
• Verra N, De Jong D, Bex A, et al. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy. Eur Urol. 2005;48(3):527–533. doi:10.1016/j.eururo.2005.03.03116115526
   PubMedGoogle Scholar
• Van Poppel H, Joniau S, Van Gool SW. Vaccine therapy in patients with renal cell carcinoma. Eur Urol. 2009;55(6):1333–1344. doi:10.1016/j.eururo.2009.01.04319201522
   PubMedGoogle Scholar
• Asemissen AM, Brossart P. Vaccination strategies in patients with renal cell carcinoma. Cancer Immunol Immunother. 2009;58(7):1169–1174. doi:10.1007/s00262-009-0706-719360405
   PubMed Web of Science ®Google Scholar
• Anguille S, Smits EL, Lion E, Van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014;15(7):257–267. doi:10.1016/S1470-2045(13)70585-024534291
   PubMed Web of Science ®Google Scholar
• Zhang AL, Purath U, Tarner IH, et al. Natural killer cells trigger differentiation of monocytes into dendritic cells. Blood. 2007;110(7):2484–2493. doi:10.1182/blood-2007-02-07636417626840
   PubMedGoogle Scholar
• Wang Z, Rao DD, Senzer N, Nemunaitis J. RNA interference and cancer therapy. Pharm Res. 2011:2983–2995. doi:10.1007/s11095-011-0604-5
   Google Scholar
• Li M, Qian H, Ichim TE, et al. Induction of RNA interference in dendritic cells. Immunol Res. 2004;30(2):215–230. doi:10.1385/IR:30:2:21515477662
   PubMedGoogle Scholar
• Liu S, Liu D, Ji M, et al. An indoleamine 2, 3-dioxygenase siRNA nanoparticle-coated and Trp2-displayed recombinant yeast vaccine inhibits melanoma tumor growth in mice. J Control Release. 2018;273:1–12. doi:10.1016/j.jconrel.2018.01.01329355622
   PubMedGoogle Scholar
• Filipowicz W, Jaskiewicz L, Kolb FA, Pillai RS. Post-transcriptional gene silencing by siRNAs and miRNAs. Curr Opin Struct Biol. 2005;15:331–341. doi:10.1016/j.sbi.2005.05.00615925505
   PubMed Web of Science ®Google Scholar
• He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522–531. doi:10.1038/nrg137915211354
   PubMed Web of Science ®Google Scholar
• Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature. 2009;457(7228):426–433. doi:10.1038/nature0775819158789
   PubMed Web of Science ®Google Scholar
• Tatiparti K, Sau S, Kashaw S, Iyer A. siRNA delivery strategies: a comprehensive review of recent developments. Nanomaterials. 2017;7(4):77. doi:10.3390/nano7040077
   Web of Science ®Google Scholar
• Massadeh S, Al Aamery M. Nano-materials for gene therapy: an efficient way in overcoming challenges of gene delivery. J Biosens Bioelectron. 2016;07(01):1–12. doi:10.4172/2155-6210.1000195
   Google Scholar
• Morris KV, Chan SW-L, Jacobsen SE, Looney DJ. Small interfering RNA-induced transcriptional gene silencing in human cells. Cell. 2004;305(1):1289–1293.
   Google Scholar
• Li J, Xue S, Mao ZW. Nanoparticle delivery systems for siRNA-based therapeutics. J Mater Chem B. 2016;4(41):6620–6639. doi:10.1039/c6tb01462c
   PubMed Web of Science ®Google Scholar
• Oh YK, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev. 2009;61(10):850–862. doi:10.1016/j.addr.2009.04.01819422869
   PubMed Web of Science ®Google Scholar
• Chen M, Du Q, Zhang H-Y, Wahlestedt C, Liang Z. Vector-based siRNA delivery strategies for high-throughput screening of novel target genes. J RNAi Gene Silencing. 2005;1(1):5–11.19771198
   PubMedGoogle Scholar
• Lee NS, Dohjima T, Bauer G, et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol. 2002;20(5):500–505. doi:10.1038/nbt0502-50011981565
   PubMed Web of Science ®Google Scholar
• Moffatt S. siRNA-based nanoparticles for cancer therapy: hurdles and hopes. MOJ Proteomics Bioinforma. 2017;4(6):4–6. doi:10.15406/mojpb.2016.04.00142
   Google Scholar
• Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov. 2010;9(1):57–67. doi:10.1038/nrd301020043028
   PubMed Web of Science ®Google Scholar
• Marques JT, Williams BRG. Activation of the mammalian immune system by siRNAs. Nat Biotechnol. 2005;23:1399. doi:10.1038/nbt116116273073
   PubMed Web of Science ®Google Scholar
• Alagia A, Eritja R. siRNA and RNAi optimization. Wiley Interdiscip Rev RNA. 2016;7(3):316–329. doi:10.1002/wrna.133726840434
   PubMed Web of Science ®Google Scholar
• Bramsen JB, Pakula MM, Hansen TB, et al. A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res. 2010;38(17):5761–5773. doi:10.1093/nar/gkq34120453030
   PubMed Web of Science ®Google Scholar
• Suter SR, Ball-Jones A, Mumbleau MM, et al. Controlling miRNA-like off-target effects of an siRNA with nucleobase modifications. Org Biomol Chem. 2017;15(47):10029–10036. doi:10.1039/c7ob02654d29164215
   PubMed Web of Science ®Google Scholar
• Alagia A, Jorge AF, Aviñó A, et al. Exploring PAZ/3′-overhang interaction to improve siRNA specificity. A combined experimental and modeling study. Chem Sci. 2018;9(8):2074–2086. doi:10.1039/c8sc00010g29719684
   PubMedGoogle Scholar
• Kang HS, Lee D, Li CJ, et al. Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects. Mol Ther. 2009;17(4):725–732. doi:10.1038/mt.2008.29819156133
   PubMedGoogle Scholar
• Sioud M. Advances in RNA sensing by the immune system: separation of siRNA unwanted effects from RNA interference. Methods Mol Biol. 2010;629:33–52. doi:10.1007/978-1-60761-657-3_320387141
   PubMedGoogle Scholar
• Eberle F, Peter M, Richert C, et al. Modifications in small interfering RNA that separate immunostimulation from RNA interference. J Immunol. 2014;180(5):3229–3237. doi:10.4049/jimmunol.180.5.3229
   Google Scholar
• Slobodkin G, Wilkinson L, Pence C, et al. Versatile cationic lipids for siRNA delivery. J Control Release. 2011;158(2):269–276. doi:10.1016/j.jconrel.2011.11.00622100441
   PubMedGoogle Scholar
• Tam YYC, Chen S, Cullis PR. Advances in lipid nanoparticles for siRNA delivery. Pharmaceutics. 2013;5(3):498–507. doi:10.3390/pharmaceutics503049824300520
   PubMedGoogle Scholar
• Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28:172. doi:10.1038/nbt.160220081866
   PubMed Web of Science ®Google Scholar
• Love KT, Mahon KP, Christopher G, et al. Correction for Love et al., Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci. 2010;107(21):9915. doi:10.1073/pnas.1005136107
   Web of Science ®Google Scholar
• Abrams MT, Koser ML, Seitzer J, et al. Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. Mol Ther. 2010;18(1):171–180. doi:10.1038/mt.2009.20819738601
   PubMed Web of Science ®Google Scholar
• Grijalvo S, Puras G, Zárate J, et al. Cationic niosomes as non-viral vehicles for nucleic acids: challenges and opportunities in gene delivery. Pharmaceutics. 2019;11:2. doi:10.3390/pharmaceutics11020050
   Web of Science ®Google Scholar
• Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chem Rev. 2015;115(19):10938–10966. doi:10.1021/acs.chemrev.5b0004626010257
   PubMed Web of Science ®Google Scholar
• Derycke A. Liposomes for photodynamic therapy. Adv Drug Deliv Rev. 2003;56(1):17–30. doi:10.1016/j.addr.2003.07.014
   Web of Science ®Google Scholar
• Minko T, Pakunlu RI, Wang Y, Khandare JJ, Saad M. New generation of liposomal drugs for cancer. Anticancer Agents Med Chem. 2014;6(6):537–552. doi:10.2174/187152006778699095
   Google Scholar
• Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014;66:110–116. doi:10.1016/j.addr.2013.12.00824384374
   PubMed Web of Science ®Google Scholar
• Duchemin A, Evrard B, Piel G, Sanna V, Lechanteur A, Mottet D. Cationic liposomes carrying siRNA: impact of lipid composition on physicochemical properties, cytotoxicity and endosomal escape. Nanomaterials. 2018;8(5):270. doi:10.3390/nano8050270
   Web of Science ®Google Scholar
• Santel A, Aleku M, Keil O, et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. 2006;13(16):1222–1234. doi:10.1038/sj.gt.330277716625243
   PubMedGoogle Scholar
• Aleku M, Schulz P, Keil O, et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res. 2008;68(23):9788–9798. doi:10.1158/0008-5472.CAN-08-242819047158
   PubMed Web of Science ®Google Scholar
• Wu SY, McMillan NAJ. Lipidic systems for in vivo siRNA delivery. Aaps J. 2009;11(4):639–652. doi:10.1208/s12248-009-9140-119757082
   PubMed Web of Science ®Google Scholar
• Landen CN, Merritt WM, Mangala LS, et al. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther. 2006;5(12):1708–1713. doi:10.4161/cbt.5.12.346817106249
   PubMed Web of Science ®Google Scholar
• Cheng Y, Ji Y. RGD-modified polymer and liposome nanovehicles: recent research progress for drug delivery in cancer therapeutics. Eur J Pharm Sci. 2019;128:8–17. doi:10.1016/j.ejps.2018.11.02330471410
   PubMed Web of Science ®Google Scholar
• Mattern-Schain SI, Fisher RK, West PC, et al. Cell mimetic liposomal nanocarriers for tailored delivery of vascular therapeutics. Chem Phys Lipids. 2019;218:149–157. doi:10.1016/j.chemphyslip.2018.12.00930582896
   PubMedGoogle Scholar
• Zimmermann TS, Lee ACH, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature. 2006;441(1):111–114. doi:10.1038/nature0468816565705
   PubMedGoogle Scholar
• Ho W, Zhang XQ, Xu X. Biomaterials in siRNA delivery: a comprehensive review. Adv Healthc Mater. 2016;5(21):2715–2731. doi:10.1002/adhm.20160041827700013
   PubMed Web of Science ®Google Scholar
• Sood V, Honko AN, MacLachlan I, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010;375(9729):1896–1905. doi:10.1016/s0140-6736(10)60357-120511019
   PubMedGoogle Scholar
• Nikam RR, Gore KR. Journey of siRNA: clinical developments and targeted delivery. Nucleic Acid Ther. 2018;28(4):209–224. doi:10.1089/nat.2017.071529584585
   PubMed Web of Science ®Google Scholar
• Lin PJC, Tam YK. Chapter 9 - controlling protein expression by delivery of RNA therapeutics using lipid nanoparticles In: Filice M, Ruiz-Cabello JBT-NA-N editors. Micro and Nano Technologies. Amsterdam, the Netherlands: Elsevier; 2019:277–310. doi:10.1016/B978-0-12-814470-1.00009-5.
   Google Scholar
• Zhao J, Weng G, Li J, Zhu J, Zhao J. Polyester-based nanoparticles for nucleic acid delivery. Mater Sci Eng C. 2018;92:983–994. doi:10.1016/j.msec.2018.07.027
   PubMed Web of Science ®Google Scholar
• Rozema DB, Lewis DL, Wakefield DH, et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci. 2007;104(32):12982LP–12987. doi:10.1073/pnas.070377810417652171
   PubMedGoogle Scholar
• Wagner E. polymers for sirna delivery: inspired by viruses to be targeted, dynamic, and precise. Acc Chem Res. 2012;45(7):1005–1013. doi:10.1021/ar200223222191535
   PubMed Web of Science ®Google Scholar
• Cheng R, Feng F, Meng F, Deng C, Feijen J, Zhong Z. Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery. J Control Release. 2011;152(1):2–12. doi:10.1016/j.jconrel.2011.01.03021295087
   PubMed Web of Science ®Google Scholar
• Farra R, Musiani F, Perrone F, et al. Polymer-mediated delivery of siRNAs to hepatocellular carcinoma: variables affecting specificity and effectiveness. Molecules. 2018;23(4). doi:10.3390/molecules23040777
   PubMed Web of Science ®Google Scholar
• Parmar RG, Poslusney M, Busuek M, et al. Novel endosomolytic poly(amido amine) polymer conjugates for systemic delivery of siRNA to hepatocytes in rodents and nonhuman primates. Bioconjug Chem. 2014;25(5):896–906. doi:10.1021/bc400527e24742200
   PubMedGoogle Scholar
• Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater. 2013;12(11):967–977. doi:10.1038/nmat376524150415
   PubMed Web of Science ®Google Scholar
• Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm. 2009;6(3):659–668. doi:10.1021/mp900015y19267452
   PubMed Web of Science ®Google Scholar
• O’Mahony AM, Godinho BMDC, Ogier J, et al. Click-modified cyclodextrins as nonviral vectors for neuronal siRNA delivery. ACS Chem Neurosci. 2012;3(10):744–752. doi:10.1021/cn300037223077718
   PubMed Web of Science ®Google Scholar
• Díaz-Moscoso A, Le Gourriérec L, Gómez-García M, et al. Polycationic amphiphilic cyclodextrins for gene delivery: synthesis and effect of structural modifications on plasmid DNA complex stability, cytotoxicity, and gene expression. Chem A Eur J. 2009;15(46):12871–12888. doi:10.1002/chem.200901149
   PubMed Web of Science ®Google Scholar
• Miele E, Spinelli GP, Miele E, et al. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomedicine. 2012;7:3637–3657. doi:10.2147/IJN.S2369622915840
   PubMed Web of Science ®Google Scholar
• Sica G, Chen Z, Wang Z, et al. RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy. Clin Cancer Res. 2013;19(13):3416–3428. doi:10.1158/1078-0432.ccr-13-007323719266
   PubMedGoogle Scholar
• Davis ME, Seligson D, Tolcher A, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464(7291):1067–1070. doi:10.1038/nature0895620305636
   PubMed Web of Science ®Google Scholar
• Hovgaard MB, Rahbek UL, Glud SZ, et al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther. 2006;14(4):476–484. doi:10.1016/j.ymthe.2006.04.01016829204
   PubMedGoogle Scholar
• Dai K, Winnik F, Qiu X, et al. Low molecular weight chitosan conjugated with folate for siRNA delivery in vitro: optimization studies. Int J Nanomedicine. 2012;7:5833. doi:10.2147/ijn.s3556723209368
   PubMedGoogle Scholar
• De Smedt SC, Nysten B, Le Duff CS, et al. Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase stability and efficiency. J Control Release. 2014;176:54–63. doi:10.1016/j.jconrel.2013.12.02624389132
   PubMedGoogle Scholar
• Kim YK, Minai-Tehrani A, Lee JH, Cho CS, Cho MH, Jiang HL. Therapeutic efficiency of folated poly(ethylene glycol)-chitosan-graft-polyethylenimine-Pdcd4 complexes in H-ras12V mice with liver cancer. Int J Nanomedicine. 2013;8:1489–1498. doi:10.2147/IJN.S4294923620665
   PubMed Web of Science ®Google Scholar
• Kankala RK, Lin XF, Song HF, et al. Supercritical fluid-assisted decoration of nanoparticles on porous microcontainers for codelivery of therapeutics and inhalation therapy of diabetes. ACS Biomater Sci Eng. 2018;4(12):4225–4235. doi:10.1021/acsbiomaterials.8b00992
   PubMed Web of Science ®Google Scholar
• Xu P-Y, Kankala RK, Pan Y-J, Yuan H, Wang S-B, Chen A-Z. Overcoming multidrug resistance through inhalable siRNA nanoparticles-decorated porous microparticles based on supercritical fluid technology. Int J Nanomedicine. 2018;13:4685–4698. doi:10.2147/IJN.S16939930154654
   PubMed Web of Science ®Google Scholar
• Wang S-B, Chen A-Z, Tang N, Su X-Q, Kang Y-Q. Preparation and antitumor effect evaluation of composite microparticles co-loaded with siRNA and paclitaxel by a supercritical process. J Mater Chem B. 2015;3(31):6439–6447. doi:10.1039/c5tb00715a
   PubMed Web of Science ®Google Scholar
• Kankala RK, Chen B-Q, Liu C-G, Tang H-X, Wang S-B, Chen A-Z. Solution-enhanced dispersion by supercritical fluids: an ecofriendly nanonization approach for processing biomaterials and pharmaceutical compounds. Int J Nanomedicine. 2018;13:4227–4245. doi:10.2147/IJN.S16612430087558
   PubMed Web of Science ®Google Scholar
• Licciardi M, Li Volsi A, Sardo C, Mauro N, Cavallaro G, Giammona G. Inulin-ethylenediamine coated SPIONs magnetoplexes: a promising tool for improving siRNA delivery. Pharm Res. 2015;32(11):3674–3687. doi:10.1007/s11095-015-1726-y26085039
   PubMedGoogle Scholar
• Sardo C, Farra R, Licciardi M, et al. Development of a simple, biocompatible and cost-effective Inulin-Diethylenetriamine based siRNA delivery system. Eur J Pharm Sci. 2015;75:60–71. doi:10.1016/j.ejps.2015.03.02125845631
   PubMed Web of Science ®Google Scholar
• Sardo C, Craparo EF, Porsio B, Giammona G, Cavallaro G. Improvements in rational design strategies of inulin derivative polycation for siRNA delivery. Biomacromolecules. 2016;17(7):2352–2366. doi:10.1021/acs.biomac.6b0028127238382
   PubMedGoogle Scholar
• Aigner A. Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo. J Biomed Biotechnol. 2006;2006:1–15. doi:10.1155/JBB/2006/71659
   Web of Science ®Google Scholar
• Akhtar S, Benter IF. Review series nonviral delivery of synthetic siRNAs in vivo. J Clin Invest. 2007;117(12):3623–3632. doi:10.1172/JCI33494.following18060020
   PubMed Web of Science ®Google Scholar
• Judge A, Fritz EA, Phelps JR, et al. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis. 2006;193(12):1650–1657. doi:10.1086/50426716703508
   PubMedGoogle Scholar
• Bai A, Chen J, Filip L, Nguyen T, Ge Q, Eisen HN. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci. 2004;101(23):8676–8681. doi:10.1073/pnas.040248610115173599
   PubMedGoogle Scholar
• Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 2004;12:461. doi:10.1038/sj.gt.3302425
   Web of Science ®Google Scholar
• Akhtar S, Benter I. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev. 2007;59(2–3):164–182. doi:10.1016/j.addr.2007.03.01017481774
   PubMed Web of Science ®Google Scholar
• Pandey AP, Sawant KK. Polyethylenimine: A versatile, multifunctional non-viral vector for nucleic acid delivery. Mater Sci Eng C. 2016;68:904–918. doi:10.1016/j.msec.2016.07.066
   PubMed Web of Science ®Google Scholar
• Wang J, Lu Z, Wientjes MG, Au JL-S. Delivery of siRNA therapeutics: barriers and carriers. Aaps J. 2010;12(4):492–503. doi:10.1208/s12248-010-9210-420544328
   PubMed Web of Science ®Google Scholar
• Fornaguera C, Grijalvo S, Galán M, et al. Novel non-viral gene delivery systems composed of carbosilane dendron functionalized nanoparticles prepared from nano-emulsions as non-viral carriers for antisense oligonucleotides. Int J Pharm. 2015;478(1):113–123. doi:10.1016/j.ijpharm.2014.11.03125448573
   PubMedGoogle Scholar
• Khan A, Benboubetra M, Sayyed PZ, et al. Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. J Drug Target. 2004;12(6):393–404. doi:10.1080/1061186040000385815545089
   PubMed Web of Science ®Google Scholar
• Svenson S, Case RI, Cole RO, et al. Tumor selective silencing using an RNAi-conjugated polymeric nanopharmaceutical. Mol Pharm. 2016;13(3):737–747. doi:10.1021/acs.molpharmaceut.5b0060826835715
   PubMedGoogle Scholar
• Byeon Y, Lee J-W, Choi WS, et al. CD44-targeting PLGA nanoparticles incorporating paclitaxel and FAK siRNA overcome chemoresistance in epithelial ovarian cancer. Cancer Res. 2018;78(21):6247LP–6256. doi:10.1158/0008-5472.CAN-17-387130115698
   PubMedGoogle Scholar
• Winkler J. Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides. Ther Deliv. 2011;2(7):891–905. doi:10.4155/tde.11.5622318893
   PubMedGoogle Scholar
• Kaneshiro TL, Lu ZR. Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials. 2009;30(29):5660–5666. doi:10.1016/j.biomaterials.2009.06.02619595449
   PubMed Web of Science ®Google Scholar
• Bhatia S, Zhu H, Birjiniuk A, et al. Functional delivery of siRNA in mice using dendriworms. ACS Nano. 2009;3(9):2495–2504. doi:10.1021/nn900201e19673534
   PubMedGoogle Scholar
• Zhou J, Shum KT, Burnett JC, Rossi JJ. Nanoparticle-based delivery of RNAi therapeutics: progress and challenges. Pharmaceuticals. 2013;6(1):85–107. doi:10.3390/ph601008523667320
   PubMedGoogle Scholar
• Cheung W, Pontoriero F, Taratula O, Chen AM, He H. DNA and carbon nanotubes as medicine. Adv Drug Deliv Rev. 2010;62(6):633–649. doi:10.1016/j.addr.2010.03.00720338203
   PubMedGoogle Scholar
• Lynn Kirkpatrick D, Weiss M, Naumov A, Bartholomeusz G, Bruce Weisman R, Gliko O. Carbon nanotubes: solution for the therapeutic delivery of siRNA? Materials (Basel). 2012;5(2):278–301. doi:10.3390/ma502027828817045
   PubMedGoogle Scholar
• Zhang Z, Yang X, Zhang Y, et al. Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin Cancer Res. 2006;12(16):4933–4939. doi:10.1158/1078-0432.CCR-05-283116914582
   PubMed Web of Science ®Google Scholar
• Jiang Y, Huo S, Hardie J, Liang X-J, Rotello VM. Progress and perspective of inorganic nanoparticle-based siRNA delivery systems. Expert Opin Drug Deliv. 2016;13(4):547–559. doi:10.1517/17425247.2016.113448626735861
   PubMed Web of Science ®Google Scholar
• Gindy ME, Prud’homme RK. Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy. Expert Opin Drug Deliv. 2009;6(8):865–878. doi:10.1517/1742524090293290819637974
   PubMed Web of Science ®Google Scholar
• Sangvanich T, Bejan D, Gu S, Yantasee W, Reda M, Ngamcherdtrakul W. Lyophilization and stability of antibody-conjugated mesoporous silica nanoparticle with cationic polymer and PEG for siRNA delivery. Int J Nanomedicine. 2018;13:4015–4027. doi:10.2147/ijn.s16439330022824
   PubMedGoogle Scholar
• Tiash S, Kamaruzman NIB, Chowdhury EH. Carbonate apatite nanoparticles carry siRNA(s) targeting growth factor receptor genes egfr1 and erbb2 to regress mouse breast tumor. Drug Deliv. 2017;24(1):1721–1730. doi:10.1080/10717544.2017.139638529119846
   PubMed Web of Science ®Google Scholar
• Courty J, Latorre A, Villanueva A, et al. Efficient treatment of breast cancer xenografts with multifunctionalized iron oxide nanoparticles combining magnetic hyperthermia and anti-cancer drug delivery. Breast Cancer Res. 2015;17(1):1–17. doi:10.1186/s13058-015-0576-125567532
   PubMedGoogle Scholar
• Cai D, Long R, Liu Y, et al. Bacterial magnetosomes-based nanocarriers for co-delivery of cancer therapeutics in vitro. Int J Nanomedicine. 2018;13:8269–8279. doi:10.2147/ijn.s18050330584299
   PubMedGoogle Scholar
• Wu Z, Shen J, Zhang L-M, et al. Magnetic cationic amylose nanoparticles used to deliver survivin-small interfering RNA for gene therapy of hepatocellular carcinoma in vitro. Nanomaterials. 2017;7(5):110. doi:10.3390/nano7050110
   Web of Science ®Google Scholar
• Roca M, Aj H. Probing cells with noble metal nanoparticle aggregates. Nanomedicine. 2008;3(4):555–565. doi:10.2217/17435889.3.4.55518694317
   PubMedGoogle Scholar
• Xu ZP, Zeng QH, Lu GQ, Yu AB. Inorganic nanoparticles as carriers for efficient cellular delivery. Chem Eng Sci. 2006;61(3):1027–1040. doi:10.1016/j.ces.2005.06.019
   Web of Science ®Google Scholar
• Wong JKL, Habib N, Seifalian AM, Mohseni R, Hamidieh AA, MacLaren RE. Will nanotechnology bring new hope for gene delivery? Trends Biotechnol. 2017;35(5):434–451. doi:10.1016/j.tibtech.2016.12.00928108036
   PubMed Web of Science ®Google Scholar
• Mendes R, Fernandes AR, Baptista PV. Gold nanoparticle approach to the selective delivery of gene silencing in cancer-The case for combined delivery? Genes (Basel). 2017;8(3):94. doi:10.3390/genes8030094
   PubMed Web of Science ®Google Scholar
• Hou W, Wei P, Kong L, Guo R, Wang S, Shi X. Partially PEGylated dendrimer-entrapped gold nanoparticles: A promising nanoplatform for highly efficient DNA and siRNA delivery. J Mater Chem B. 2016;4(17):2933–2943. doi:10.1039/c6tb00710d
   PubMed Web of Science ®Google Scholar
• Tokatlian T, Segura T. siRNA applications in nanomedicine. Wiley Interdiscip Rev Nanomedicine Nanobiotechnology. 2010;2(3):305–315. doi:10.1002/wnan.8120135697
   PubMed Web of Science ®Google Scholar
• Benitez-Del-Castillo JM, Moreno-Montañés J, Jiménez-Alfaro I, et al. Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease. Investig Ophthalmol Vis Sci. 2016;57(14):6447–6454. doi:10.1167/iovs.16-2030327893109
   PubMed Web of Science ®Google Scholar
• Perales JC, Marquez VE, Eritja R, Ocampo SM, Terrazas M. Effect of north bicyclo[3.1.0]hexane 2′-Deoxy-pseudosugars on RNA Interference: a novel class of siRNA modification. ChemBioChem. 2011;12(7):1056–1065. doi:10.1002/cbic.20100079121452187
   PubMedGoogle Scholar
• Grijalvo S, Alagia A, Jorge AF, Eritja R. Covalent strategies for targeting messenger and non-coding RNAs: an updated review on siRNA, miRNA and antimiR conjugates. Genes (Basel). 2018;9:2. doi:10.3390/genes9020074
   Web of Science ®Google Scholar
• Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432(7014):173–178. doi:10.1038/nature0312115538359
   PubMed Web of Science ®Google Scholar
• Manoharan M, Andree C, Amaya P, et al. Identification of siRNA delivery enhancers by a chemical library screen. Nucleic Acids Res. 2015;43(16):7984–8001. doi:10.1093/nar/gkv76226220182
   PubMedGoogle Scholar
• Nair JK, Willoughby JLS, Chan A, et al. Multivalent N-Acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc. 2014;136(49):16958–16961. doi:10.1021/ja505986a25434769
   PubMed Web of Science ®Google Scholar
• Meyers RE, Weiss GJ, Clausen VA, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013;3(4):406–417. doi:10.1158/2159-8290.cd-12-042923358650
   PubMedGoogle Scholar
• Donahoe JS, Nahrendorf M, Langer R, et al. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol. 2012;7(6):389–393. doi:10.1038/nnano.2012.7322659608
   PubMedGoogle Scholar
• Salvans C, Brun-Heath I, Ivani I, et al. Rational design of novel N-alkyl-N capped biostable RNA nanostructures for efficient long-term inhibition of gene expression. Nucleic Acids Res. 2016;44(9):4354–4367. doi:10.1093/nar/gkw16926975656
   PubMedGoogle Scholar
• He C, Weizmann Y, Lin W, Liu D, Gannett TR, Chen G. Enzymatic synthesis of periodic DNA nanoribbons for intracellular pH sensing and gene silencing. J Am Chem Soc. 2015;137(11):3844–3851. doi:10.1021/ja512665z25622178
   PubMedGoogle Scholar
• Ruan W, Zheng M, An Y, et al. DNA nanoclew templated spherical nucleic acids for siRNA delivery. Chem Commun. 2018;54(29):3609–3612. doi:10.1039/c7cc09257a
   PubMed Web of Science ®Google Scholar
• Jorge AF, Eritja R. Overview of DNA self-assembling: progresses in biomedical applications. Pharmaceutics. 2018;10:4. doi:10.3390/pharmaceutics10040268
   Web of Science ®Google Scholar
• Li H, Wang L, Fan C, Gu H, Hu Q. DNA nanotechnology-enabled drug delivery systems. Chem Rev. 2018. doi:10.1021/acs.chemrev.7b00663
   Web of Science ®Google Scholar
• Ni Z, Hui P. Emerging pharmacologic therapies for wet age-related macular degeneration. Ophthalmologica. 2009;223(6):401–410. doi:10.1159/00022892619622904
   PubMedGoogle Scholar
• Chakraborty C, Sharma AR, Sharma G, Doss CGP, Lee S-S. Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine. Mol Ther Nucleic Acids. 2017;8:132–143. doi:10.1016/j.omtn.2017.06.00528918016
   PubMedGoogle Scholar
• Xin Y, Huang M, Guo WW, Huang Q, Zhang L, Jiang G. Nano-based delivery of RNAi in cancer therapy. Mol Cancer. 2017;16(1):1–9. doi:10.1186/s12943-017-0683-y28093071
   PubMedGoogle Scholar
• Shim MS, Wong S, Kwon YJ. SiRNA as a conventional drug in the clinic? Challenges and current technologies. Drug Discov Today Technol. 2012;9(2):e167–e173. doi:10.1016/j.ddtec.2012.01.003
   Google Scholar
• Ferrari M. Vectoring siRNA therapeutics into the clinic. Nat Rev Clin Oncol. 2010;7:485. doi:10.1038/nrclinonc.2010.13120798696
   PubMedGoogle Scholar
• Santel A, Kaufmann J, Strumberg D, et al. First-in-human phase I Study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. J Clin Oncol. 2014;32(36):4141–4148. doi:10.1200/jco.2013.55.037625403217
   PubMedGoogle Scholar
• Tabernero J, Shapiro GI, LoRusso PM, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013;3(4):406LP–417. doi:10.1158/2159-8290.CD-12-042923358650
   PubMedGoogle Scholar
• Tolcher AW, Papadopoulos KP, Patnaik A, et al. Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors. J Clin Oncol. 2015;33(15_suppl):11006. doi:10.1200/jco.2015.33.15_suppl.11006
   Web of Science ®Google Scholar
• Wagner MJ, Sood AK, Lopez-Berestein G, et al. Preclinical mammalian safety studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). Mol Cancer Ther. 2017;16(6):1114–1123. doi:10.1158/1535-7163.mct-16-054128265009
   PubMed Web of Science ®Google Scholar
• Golan T, Khvalevsky EZ, Hubert A, et al. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget. 2015;6(27):24560–24570. doi:10.18632/oncotarget.418326009994
   PubMedGoogle Scholar
• Mahmoodzadeh H, Moazzen F, Mehmandoost N, et al. Cloning and expression of C2 and V Domains of ALCAM Protein in E. coli BL21 (DE3). Clin Microbiol Open Access. 2017;06(01):1–6. doi:10.4172/2327-5073.1000271
   Google Scholar
• Dana H, Marmari V, Mazraeh A, Ghamari A, Forghanifard MM. Cloning and expression of the V-domain of the CD166 in prokaryotic host cell. Int J Cancer Ther Oncol. 2017;5(1). http://ijcto.org/index.php/IJCTO/article/view/ijcto51.10.
   Google Scholar
• Dana H. CD166 as a stem cell marker? A potential target for therapy colorectal cancer? J Stem Cell Res Ther. 2017;1(6):6–9. doi:10.15406/jsrt.2016.01.00041
   Google Scholar